Fractyl Health (GUTS) Receivables (2023 - 2024)
Fractyl Health's (GUTS) quarterly Receivables came in at $22000.0 in Q2 2024, up 46.67% on a QoQ basis from $15000.0 in Q1 2024.
Fractyl Health (GUTS) Receivables (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of Receivables data on file, last reported at $22000.0 in Q2 2024.
- Quarterly Receivables changed N/A year-over-year to $22000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $22000.0 (changed N/A YoY) and the FY2023 annual result came in at $22000.0, changed N/A from the prior year.
- Receivables advanced to $22000.0 in Q2 2024, from $15000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $22000.0 in Q4 2023 to a low of $15000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 22,000.00 |